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vivo data available, although this is a more appropriate 
reflection of the complex biological response.  
RBE is often established as measured by cell death, but 
emerging evidence also demonstrate an altered response in 
the surviving cells. This is both evident for high LET 
radiation, but also for proton radiation. This differential 
biological effect is not only relevant in the tumour, but also 
in the normal tissue. Current research in particle radiobiology 
is, in addition to the RBE, focusing on the molecular tissue 
response, and on the signalling pathways. Gene expression 
response in a panel of primary human fibroblasts, established 
from patients with known response to xray radiation in 
regards to late tissue damage, irradiated in vitro with 
different radiation qualities, has evaluated the effect of 
particle irradiation at different positions in the beam. This 
enlightens the heterogeneity in patient response to proton 
irradiation, individual biological variations and the 
differential effect of proton irradiation. This presentation 
will focus on the available experimental data on normal 
tissue response after irradiation with protons or heavier ions.  
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Many technological developments attempt to reduce dose to 
normal tissues in order to reduce normal tissue damage. 
However, optimal use of such technologies requires 
knowledge of mechanisms underlying normal tissue damage. 
Therefore, normal tissue effects were studied using highly 
accurate proton irradiation to different regions and volumes 
in various rat organs. 
Rats were irradiated using high-energy protons. Collimator 
design was based on X-ray imaging (spinal cord), MRI (parotid 
gland) or CT scans (heart, lung) of age, sex and weight 
matched rats. This typically resulted in 2-4% uncertainty in 
irradiated volume of that organ. For partial irradiation of the 
spinal cord an in-line X-ray imager was used to yield a 
positioning accuracy of 0.1 mm. Finally, non-uniform 
irradiations were facilitated by sequential use of different 
collimators. Hind leg paralysis, breathing frequency chances 
and salivary flow rate and tissue histo-pathology were used to 
assess organ response. 
Spinal cord: Next to irradiated volume, low doses surrounding 
small volumes with a high dose effects were found to strongly 
impact the tolerance dose. In addition, the tolerance dose 
strongly depended on the shape of the dose distribution, 
independent of irradiated volume. Taken together this 
indicates that irradiated volume is not good predictor of 
toxicity. However, a model including tissue repair originating 
from non-irradiated tissue over a limited distance could 
explain the observed effects. Taken together these results 
suggest that regeneration plays an important role in the 
response of the spinal cord. 
Parotid gland: We demonstrated that the response of the 
parotid gland critically depends on dose to its stem cells, 
mainly located in its major ducts. The importance of this 
anatomical location was confirmed in a retrospective analysis 
of clinical data. A prospective clinical trial to validate this 
finding is in progress. 
Lung: Volume dependent mechanisms of lung toxicities were 
observed, where high volumes with low dose limiting early 
vascular/inflammatory responses inducing pulmonary 
hypertension and consequential cardiac problems, whereas 
low volumes displayed high or even no dose limiting late 
fibrotic response. Moreover, inclusion of the heart in the 
irradiation field strongly enhanced early lung responses. 
In summary, using high-precision proton irradiation of rat 
organs we elucidated several mechanisms and critical targets 
for normal tissue damage. In general we found that, rather 
than dose to the organ, the development of toxicity strongly 
related to dose to functional sub-structures within the organ 
or even in other organs. In general, in more parallel 
organized tissues it seems that a high dose to a small volume 
is better that a low dose to a large volume. Maintaining or 
enhancing the regenerating potential of the normal tissue 
seems warranted to further optimize radiation therapy. 
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Treatment of verterbral metastasis can be compex, involving 
medical treatment, radiotherapy, suregry or newer technique 
such as thermal ablation and vertebroplasty. The purpose of 
vertebral metastasis treatment is to rapidly improve the 
quality of life of the patients and to restore the mechanical 
properties of the spinal column and to a lesser extend to 
prevent local tumor growth.  
Minimally invasive treatment,such as vertebroplasty, 
combined or not, with thermal ablation fulfill all these 
purposes with minimal impact on the patient’s quality of life.  
Vertebroplasty is efficient in contolling the patient’s pain in 
89.7% at 1 month and 86.9% at 6 months (ref 1).  
Restoration of the mechanical properties of the spinal column 
is obtaind in 100% of cases after successful vertebroplasty 
(ref 2)  
When combined with thermal ablation (RFA or Cryoablation) 
the local reccurence rate is very low (ref 3)  
While radiation therapy remains the mainstay in the 
treatment of vertebral metastasis, it does not improve the 
stability of the vertebral column. A complimentary surgery is 
often necessary to ensure stability of the treated vertebra. 
Minimalliy invasive procedure such as thermal ablation 
combined with vertebroplasty do offer immediate pain 
control in addition to local tumor control and restoration of 
mechanical stability with a minimal impact on the patient’s 
quality of life. 
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Radiotherapy is a well-established treatment for painful 
vertebral metastases. Multiple prospective studies report 
pain response rates of 50 to 90%. Based on randomized 
studies, 8 Gy in a single fraction is the standard of care for 
painful uncomplicated bone metastases. Despite the lack of a 
dose response relationship for pain control, there is good 
rationale for dose escalation with the aim to improve upon 
existing rates of local tumour control and pain control. 
Stereotactic body radiotherapy is ideally suited to safely 
escalate the dose and improve tumour control. In order to 
optimize the potential of SBRT, adequate patient selection 
and specific technical considerations should be taken into 
account.  
PATIENT SELECTION  
Several considerations should be taken into account before 
delivering SBRT for vertebral metastases. A first 
consideration is the life expectancy of the patient, which 
should be evaluated with validated scoring systems (e.g. NRF 
score, Recursive partitioning analysis index, PRISM). Patients 
with a short life expectancy in need for palliative 
radiotherapy should be managed with short effective 
radiotherapy courses. In patients with longer life expectancy 
local control might be an important end point potentially 
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requiring a higher radiotherapy dose. A second consideration 
is the characteristic of the vertebral metastasis and divides 
the metastases into uncomplicated or complicated. A 
systematic review suggested the following working definition 
for uncomplicated bone metastases: those unassociated with 
impending or existing pathologic fracture or existing spinal 
cord compression or cauda equina compression. Although this 
definition looks straightforward it is still variable to 
interpretation and might be incomplete. The Spinal 
Instability Neoplastic Score (SINS) might help us estimate the 
risk of vertebral fracture limiting SBRT to stable and 
potentially unstable metastases. Different definitions of 
spinal cord compression are available with the minimum 
evidence for cord compression being indentation of the 
thecal sac at the level of clinical features. Finally, other 
aspects such as, primary tumour type, other metastases, 
symptoms, practical considerations, current systemic 
treatment and previous radiotherapy… should be taken into  
TECHNICAL CONSIDERATIONS  
For treatment simulation several options are available for 
patient immobilization. Independent of the system used, the 
patient must be positioned in a stable position capable for 
reproducibility of positioning, allowing the patient to feel as 
comfortable as possible. A typical CT scan length should 
extend at least 10 cm superior and inferior beyond the 
treatment field borders (slice thickness of ≤2.5 - 3 mm). CT 
contrast will help visualize the soft tissue and adjacent 
normal tissues. The International Spine Radiosurgery 
consortium developed a consensus guideline for target 
volume definition. MRI images are mandatory for delineation. 
Axial volumetric T1 and T2 sequences without gadolinium are 
a standard with ≤3 mm slice thickness. Contouring of norm al 
tissue should be standardized for example: start contouring 
at 10 cm above the target volume to 10 cm below the target 
(RTOG 0631). Different fractionation schedules exist with 
variable total doses. None of the proposed schedules is 
proven to be superior to another. In case of single fraction, 
the doses vary between 16 and 24 Gy, with a strong trend for 
increasing pain relief with higher radiation doses, particularly 
with doses ≥ 16 Gy. In case of fractionated radiotherapy, 
doses vary between 7-10 Gy for a 3 fraction schedule and 
between 5-6 Gy for a 5 fraction schedule. Most centers 
prescribe the dose (Dpr) to a % volume of the PTV. A PTV 
dose coverage of <80% of the Dpr should be avoided (RTOG 
0631). This Dpr. should be prescribed to the isocenter or 
periphery of target. To minimize the risk for toxicity it is 
advised to strictly adhere to the published dose-constraints 
keeping in mind that they are mostly unvalidated. Control 
and correction of the patient and tumor position should be 
done with volumetric or stereoscopic X-ray imaging at least 
before each treatment fraction. Extensive recommendations 
and guidelines for a stereotactic or high precision QA 
program, supplementing the QA program for linear 
accelerators can be found in literature and should be 
followed (e.g. AAPM TG 101 report).  
OUTCOME  
The International Bone Metastases Consensus Working Party 
developed guidelines for the assessment of endpoints of 
palliative radiotherapy of bone metastases. It is 
recommended to follow the proposed definitions of pain 
assessment and pain response. Toxicity should evaluated at 
follow up visits using standardized criteria such as the 
National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) v.4.0. 
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Intensity-modulated radiotherapy (IMRT) has been introduced 
in a number of disease in the late nineties for treating 
complex treatment volumes and avoiding close proximity 
organs at risk (OAR) that may be dose limiting. Fifteen years 
later, in many countries, IMRT is still not considered as a 
standard technique for treating gynaecological cancers. It is 
well accepted that, if reducing acute and chronic toxicity are 
the main endpoints, IMRT may be considered as the ideal 
technique. By contrast, if disease-related outcomes are 
considered, there are still insufficient data to recommend 
IMRT over three-dimensional conformal radiotherapy. 
Moreover, with the increased accuracy of treatment delivery 
comes the need for greater accuracy in incorporation of 
organ motion to prevent geographical misses. 
Uterus significantly moves according to the bladder and 
rectal filling. The majority of motion occurs in the anterior–
posterior and superior–inferior directions, with mean 
interfraction movements of 4–7 mm, but very large 
displacements up to more than 2 cm may occur with the 
inherent risk of poor coverage of the posterior part of the 
cervix or of the uterine fundus. Similarly, during post-
operative irradiation, the vaginal CTV changes its position 
with standard deviation of 2.3 cm into the anterior or 
posterior direction, 1.8 cm to left or right and 1.5 cm 
towards the cranial. According to the majority of studies a 
uniform CTV planning treatment volume margin of 15 mm 
would fail to encompass the CTV in 5% of fractions in post-op. 
It rises up to 32%, when the CTV includes the entire uterus. 
For intact cervical cancer, where gross disease is present, the 
significant shrinkage in tumour volume of 62% in mean, also 
contributes to potential unintended doses to normal tissues, 
but the risk is rather low.  
How to deal with motion uncertainties? 
It can be helpful to attempt to control rectum and bladder 
filling, although the compliance with instructions for bladder 
filling and for rectal emptying does not always result in 
adequate reproducibility. The construction of an ITV from CT 
images acquired with empty and full bladder is also another 
way to account for interfraction motion of the CTV. The 
implementation of IGRT on a daily basis is essential for 
judging the effectiveness of the measures previously 
outlined. However, one must never forget that the cervix or 
vaginal cuff and surrounding tissues are mobile relative to 
the bony pelvis, while the pelvic lymph nodes which are also 
part of the target are relatively fixed. Thus, the shifts to 
account for motion of the mobile target may move the pelvic 
lymph nodes out of the PTV. Consequently, care should be 
taken when shifting to ensure that nodal targets are still 
within PTV, but keeping CTV to PTV margins to 10-15 mm 
helps to find a good compromise without jeopardizing the 
OAR’s sparing. The risk of geographical misses does exist, but 
its level must be appreciated in the light of the dose 
contribution brought by the additional brachytherapy. 
Brachytherapy still plays a major role in the treatment of 
cervix carcinomas. The important dose gradient and the 
absence of target movements in relation to the inserted 
radioactive sources allow for dose escalation and 3D image 
guided adaptative procedure allows for accurate definition of 
target volumes with definition of dose volume parameters. 
Consequently a moderate under dosage of a part of CTV 
during IMRT may be compensated by the high dose delivered 
by brachytherapy.  
The concept of adaptive IMRT seems to be applicable for the 
management of the complex deformable target motion that 
occurs during radiation of gynecological cancers. The cervix–
uterus shape and position can be predicted by bladder 
volume, using a patient-specific prediction model derived 
from pre-treatment variable bladder filling CTscans. Based on 
that, a strategy called “plan of the day” has been elaborated 
and is under investigation.  
In conclusion, organ motion is not an obstacle to the use of 
IMRT as standard technique for gynecological cancer, 
especially when combined with brachytherapy, provided that 
PTV margins are not reduced and IGRT is adequately used. 
The participation to prospective studies and/or the 
registration of patients in database are strongly encouraged.  
 
 
 
 
 
